News Sentiment

AMRX sentiment intelligence

Amneal Pharmaceuticals, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 16.21 Week of 19 Jun 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+0.1% over one week, +30.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 30.5% over four weeks
Fair value 97.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
Market source 13
Sahm 7
simplywall.st 5
Investing.com 2
Seeking Alpha 2
Investing.com Nigeria 1
TradingView 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 15
Deals and strategy 5
Regulatory and legal 4
Guidance 3
Balance sheet 1
Macro sensitivity 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Sahm Direct company coverage

Top 3 Health Care Stocks That May Collapse This Quarter

The article identifies three healthcare stocks—Cardinal Health, TG Therapeutics, and Amneal Pharmaceuticals—that may be overbought according to the Relative Strength Index (RSI) as of June 15, 2026. Despite recent positive news and stock gains for all three companies, their high

Tone
Neutral 50/100
Event
Earnings
Published
15 Jun 2026 16:39
Source
Sahm
Investing.com Direct company coverage

Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD

Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $15.44, experiencing an 88% increase over the past year. This surge is attributed to the company's strong financial performance, including exceeding Q1 2026 earnings and revenue expectations, and key product developmen

Tone
Positive 92/100
Event
Earnings
Published
11 Jun 2026 12:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com

Amneal Pharmaceuticals Inc. Class A stock reached a 52-week high of $15.44, trading at $15.45 with a market capitalization of $4.87 billion, reflecting an 88% increase over the past year. This surge is attributed to the company's strong financial health and recent positive develo

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 07:09
Source
Investing.com Nigeria
Sahm Direct company coverage

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Dispensary of Hope has launched its "Hope Alliance" campaign, aimed at expanding access to longer-dated medications for low-income and uninsured patients nationwide. Amneal Pharmaceuticals is the first manufacturer to commit significant support, ensuring a reliable supply of crit

Tone
Positive 72/100
Event
Macro sensitivity
Published
10 Jun 2026 14:09
Source
Sahm
Sahm Direct company coverage

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data

Amneal Pharmaceuticals (AMRX) recently received FDA approval for its romidepsin injection and positive interim Phase 4 data for Parkinson's treatment CREXONT, contributing to an 80.45% 1-year total shareholder return. Despite being valued at $13.75 against an estimated fair value

Tone
Positive 73/100
Event
Regulatory and legal
Published
06 Jun 2026 10:39
Source
Sahm
MSN Direct company coverage

Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX)

Amneal Pharmaceuticals (AMRX) shares advanced after the company secured FDA clearance for its generic version of a cancer treatment. The approval is for a bendamustine hydrochloride injection, a chemotherapy drug used to treat chronic lymphocytic leukemia and indolent B-cell non-

Tone
Positive 72/100
Event
Regulatory and legal
Published
05 Jun 2026 21:39
Source
MSN
Investing.com Australia Direct company coverage

Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com

Amneal Pharmaceuticals (NASDAQ:AMRX) shares rose after the FDA approved its romidepsin injection solution for cutaneous T-cell lymphoma, granting 180 days of market exclusivity. This ready-to-use formulation offers an alternative to a previously withdrawn product and generated ap

Tone
Positive 72/100
Event
Regulatory and legal
Published
05 Jun 2026 10:39
Source
Investing.com Australia
Investing.com Direct company coverage

Amneal Pharmaceuticals stock gains on FDA approval for cancer drug

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) saw its shares rise in premarket trading after receiving FDA approval for its romidepsin injection solution. This drug, a histone deacetylase inhibitor for cutaneous T-cell lymphoma, offers a ready-to-use alternative and is eligible for 1

Tone
Positive 93/100
Event
Regulatory and legal
Published
04 Jun 2026 12:09
Source
Investing.com
Stock Titan Direct company coverage

[144] Amneal Pharmaceuticals, Inc. SEC Filing

This article details an SEC Form 144 filing by Amneal Pharmaceuticals, Inc. (AMRX). The filing indicates a proposed sale of 34,819 shares of Class A Common Stock by an individual through Merrill Lynch on May 11, 2026, with an aggregate market value of 450,416. The shares were acq

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 20:40
Source
Stock Titan
Sahm Direct company coverage

Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness

Amneal Pharmaceuticals (AMRX) has experienced mixed share performance despite a strong one-year return, leading to a reassessment of its valuation. The company is considered 27.1% undervalued with a narrative fair value of $17.00, driven by strategic partnerships and expansion in

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 13:08
Source
Sahm
Stock Titan Direct company coverage

Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg

Amneal Pharmaceuticals director Deborah M. Autor sold 34,819 shares of Class A Common Stock on May 11, 2026, at a weighted average price of $12.94 per share. Following this open-market transaction, her direct holdings in the company amount to 93,660 shares. The sale, valued at ap

Tone
Negative 37/100
Event
Market update
Published
12 May 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares

Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake by converting 34,819 restricted stock units into Class A Common Stock on May 7, 2026. This transaction brought her direct holdings to 128,479 Class A shares. Additionally, she was granted 19,824 new restr

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 May 2026 15:40
Source
Stock Titan
Stock Titan Direct company coverage

Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23%

Amneal Pharmaceuticals reported strong Q1 2026 financial results with net revenue reaching $723 million and GAAP net income of $62 million. The company saw a significant 23% rise in specialty drug sales, driven by key branded products, and affirmed its increased full-year 2026 gu

Tone
Positive 71/100
Event
Earnings
Published
10 May 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units

Amneal Pharmaceuticals director Jeffrey P. George recently engaged in equity compensation activities. He exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock, bringing his direct holdings to 344,614 shares. Additionally, on May

Tone
Neutral 50/100
Event
Market update
Published
09 May 2026 15:38
Source
Stock Titan